Home > Boards > US OTC > Biotechs >

Antibe Therapeutics Inc. (ATBPF)

ATBPF RSS Feed
Add ATBPF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/7/2020 12:40:02 AM - Followers: 17 - Board type: Free - Posts Today: 0

logo
http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20July%202019.pdf


http://www.antibethera.com/pipeline/ 









Gastric ulcer incidence of ATB-346 (>=3mm diameter) versus naproxen during two-week treatment period # of Subjects that Developed Ulcers 0 15 30 45 60 ATB-346 Naproxen 11 • A successful Phase 2B double blind GI safety study for ATB-346 was completed in March 2018 in 244 healthy volunteers • Validation of GI safety superiority: ATB-346 exhibited an ulceration rate of 2.5% versus 42.1% for naproxen over the two-week treatment period (p<0.0001) • ATB-346 was safe and well-tolerated Strong Phase 2B GI Safety Data 42.1% 2.5% (n = 118) (n = 126)

 

H2S Platform

HOME / H2S PLATFORM

Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.

Global NSAID sales exceed $11 billion annually, a significant market opportunity that could potentially be disrupted by Antibe’s H2S technology.

Now in Phase 2 human clinical trials, Antibe’s lead drug, ATB-346, targets mild-to-moderate pain and inflammation arising from a wide range of medical conditions. In March 2018, ATB-346 showed unequivocal superiority to naproxen in GI safety (2.5% versus 42.1% ulceration rate) in a Phase 2B double-blind clinical trial (see press release). This human proof-of-concept data replicated the results of our pre-clinical studies, and suggests Antibe has potentially surmounted the main barrier to the non-addictive control of pain and inflammation. If ATB-346 obtains regulatory approval, physicians and consumers will gain a radically safer alternative to today’s NSAIDs and to the multi-dimensional dangers of corticosteroids (used for inflammation) and opiates (used for pain).

Antibe has two other promising drug candidates in its pipeline: ATB-352, a potent pain-killer targeting the urgent global need for a safer, non-addictive analgesic for treating severe pain; and ATB-340, GI-safe derivative of aspirin for chronic prevention of cardiovascular disease and cancer chemoprevention.

Rooted in more than ten years of academic and proprietary research, Antibe’s patent-protected drug development technology enables the linking of an NSAID molecule to a hydrogen sulfide-releasing molecule. Notably, hydrogen sulfide (“H2S”) is endogenously produced and utilized throughout the body, serving as an anti-inflammatory agent and signaling molecule. Combined with an expanding scope of indications for NSAID use, the unique properties of hydrogen sulfide promise substantially improved medicines for pain and inflammation across the spectrum of human illness.

ATB-346
Novel anti-inflammatory drug that releases hydrogen sulfide (“H2S”) • Negligible GI damage: greatly superior to existing NSAIDs • No significant effect on blood pressure, unlike existing NSAIDs • Global IP with market protection to ~2030 - Patents granted in major markets (including US, Europe, Japan, China & Canada) 
ATBPF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ATBPF News: Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation 02/27/2015 09:06:00 PM
ATBPF News: Antibe Therapeutics Provides Update on Its Acute Pain Drug ATB-352 11/25/2014 07:30:00 AM
ATBPF News: Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program 10/06/2014 07:30:00 AM
ATBPF News: Antibe Therapeutics Reports on Results of AGM Voting 10/03/2014 07:30:00 AM
ATBPF News: OTC Markets Group Welcomes Antibe Therapeutics to OTCQX® 09/15/2014 07:00:00 AM
PostSubject
#252   Excellent article, thanks for posting. Mogles 04/07/20 12:40:02 AM
#251   https://klendathucap.files.wordpress.com/2020/04/antibe-atbpf2-converted.pdf djmurdock 04/06/20 11:56:28 PM
#250   I could live with that (: But I djmurdock 04/06/20 11:25:41 PM
#249   not sure why a BP couldnt do a awalkinthesun 04/06/20 06:53:37 PM
#248   $1b USD would be about $2.81 per share awalkinthesun 04/06/20 06:51:17 PM
#247   https://thedalesreport.com/investment/antibe-therapeutics-key-phase-2-data-relea djmurdock 04/06/20 02:24:13 PM
#246   Doubt it is delayed, last patients were enrolled awalkinthesun 04/06/20 12:38:27 PM
#245   Yes, I had noted mid April as the Mogles 04/03/20 06:54:54 PM
#244   Yes - phase 2b is for efficacy of Amatuer17 04/03/20 04:39:39 PM
#243   It did, I just meant this is the djmurdock 04/03/20 04:37:51 PM
#242   It did, I just meant this is the djmurdock 04/03/20 04:37:50 PM
#241   I thought the first Phase 2 already showed Mogles 04/03/20 04:18:25 PM
#240   In general, Phase2B is the most important. 70-80% djmurdock 04/03/20 11:22:34 AM
#239   Phase 2b gives proof of efficacy, so it dubt 04/03/20 11:10:35 AM
#238   Curious, why do you think this Phase 2B Mogles 04/03/20 10:56:24 AM
#237   The CEO already hinted they want to be djmurdock 04/02/20 04:04:49 PM
#236   More good press! Antibe in the BJP again. djmurdock 04/02/20 04:03:23 PM
#235   I am looking for 3-5 bagger and if Amatuer17 04/01/20 11:32:06 PM
#234   They have made it very clear their intention djmurdock 04/01/20 11:28:32 PM
#233   From a lot of the redirect coming from dubt 03/31/20 10:04:04 AM
#232   The approval is still long way - specially Amatuer17 03/30/20 06:56:14 PM
#231   Thanks! I did see someone post an email djmurdock 03/30/20 04:56:09 PM
#230   You don’t think the market cap will be Mogles 03/30/20 04:33:08 PM
#229   Good summary. The patient enrollment completed on 27th Feb Amatuer17 03/30/20 01:30:16 PM
#228   Agree, it can still be a 10-20 bagger. Mogles 03/26/20 08:13:15 PM
#227   Thanks, I agree with you as well. I djmurdock 03/26/20 01:37:55 PM
#226   Good summary. New to this board recently. Have Mogles 03/26/20 10:28:04 AM
#225   I highly recommend you check out Antibe Therapeutics djmurdock 03/25/20 07:01:47 PM
#224   anything going on besides virus scare ? waltd 03/12/20 01:10:58 PM
#223   Hot topic on Reddit: djmurdock 03/08/20 10:40:28 PM
#222   Hot topic on Reddit: djmurdock 03/08/20 10:40:27 PM
#221   Excellent news. djmurdock 02/26/20 08:54:29 PM
#220   hell yeah pennystockpal 02/25/20 02:41:54 PM
#219   positive news out on the earnings report. Study dubt 02/25/20 09:03:56 AM
#217   I hear ya and agree. Best of luck djmurdock 02/10/20 06:07:13 PM
#216   There are caveats around the $4 price and dubt 02/10/20 06:05:09 PM
#215   Yeah they are. CEO just stated they want djmurdock 02/10/20 05:52:55 PM
#214   There not in a rush to get on dubt 02/10/20 08:08:24 AM
#213   Yup, can't wait! Although the volume has finally djmurdock 02/09/20 11:43:42 AM
#212   NAS here we come NotTheFace1337 02/07/20 11:15:30 AM
#211   Very:-) Mindoro99 02/05/20 04:21:31 PM
#210   Getting interesting. treedoc 01/31/20 09:29:17 AM
#209   Wonder how big? Time will tell. https://www.businesswire.com/news/home/202001 treedoc 01/13/20 06:31:29 PM
#208   Kind of old, but some very interesting info djmurdock 01/05/20 12:00:21 PM
#207   There is a bit more chatter on Yahoo dubt 12/21/19 02:33:29 PM
#206   I've also been curious on that. a well dubt 12/21/19 11:56:45 AM
#205   i would like to know why no one waltd 12/20/19 03:32:06 PM
#204   Another delay causing SP to drop - only Amatuer17 11/29/19 10:00:03 AM
#203   I think a $500M MC is feasible if awalkinthesun 10/31/19 11:52:18 PM
#202   The trial is short - 14 days only. Amatuer17 10/29/19 05:02:30 PM
PostSubject